25 XP   0   0   10

Iovance Biotherapeutics Inc
Buy, Hold or Sell?

Let's analyse Iovance together

PenkeI guess you are interested in Iovance Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Iovance Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Iovance Biotherapeutics Inc

I send you an email if I find something interesting about Iovance Biotherapeutics Inc.

Quick analysis of Iovance (30 sec.)










What can you expect buying and holding a share of Iovance? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.94
Expected worth in 1 year
€2.22
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
€0.28
Return On Investment
2.2%

For what price can you sell your share?

Current Price per Share
€12.93
Expected price per share
€10.50 - €16.85
How sure are you?
50%

1. Valuation of Iovance (5 min.)




Live pricePrice per Share (EOD)

€12.93

Intrinsic Value Per Share

€-8.23 - €-9.45

Total Value Per Share

€-6.29 - €-7.51

2. Growth of Iovance (5 min.)




Is Iovance growing?

Current yearPrevious yearGrowGrow %
How rich?$584.6m$479.5m$146.5m23.4%

How much money is Iovance making?

Current yearPrevious yearGrowGrow %
Making money-$111m-$98.9m-$12m-10.8%
Net Profit Margin-23,290.1%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Iovance (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#92 / 1031

Most Revenue
#575 / 1031

Most Profit
#998 / 1031

Most Efficient
#986 / 1031

What can you expect buying and holding a share of Iovance? (5 min.)

Welcome investor! Iovance's management wants to use your money to grow the business. In return you get a share of Iovance.

What can you expect buying and holding a share of Iovance?

First you should know what it really means to hold a share of Iovance. And how you can make/lose money.

Speculation

The Price per Share of Iovance is €12.93. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Iovance.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Iovance, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.94. Based on the TTM, the Book Value Change Per Share is €0.07 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Iovance.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.42-3.2%-0.40-3.1%-0.35-2.7%-0.31-2.4%-0.31-2.4%
Usd Book Value Change Per Share-0.32-2.5%0.080.6%-0.11-0.8%0.120.9%0.120.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.32-2.5%0.080.6%-0.11-0.8%0.120.9%0.120.9%
Usd Price Per Share8.49-6.54-11.00-18.58-18.58-
Price to Earnings Ratio-5.09--4.12--7.89--17.57--17.57-
Price-to-Total Gains Ratio-26.49--6.21--30.88--97.97--97.97-
Price to Book Ratio4.05-2.97-6.41-10.41-10.41-
Price-to-Total Gains Ratio-26.49--6.21--30.88--97.97--97.97-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.9809725
Number of shares71
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.080.12
Usd Total Gains Per Share0.080.12
Gains per Quarter (71 shares)5.418.27
Gains per Year (71 shares)21.6333.07
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10221203323
20433406656
30655609989
4087780132122
501081000165155
601301220198188
701511440231221
801731660265254
901951880298287
1002162100331320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.018.00.00.0%0.018.00.00.0%0.018.00.00.0%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%6.012.00.033.3%6.012.00.033.3%6.012.00.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.018.00.0%0.00.018.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%6.012.00.033.3%6.012.00.033.3%6.012.00.033.3%

Fundamentals of Iovance

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Fundamental data was last updated by Penke on 2024-03-27 14:23:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Iovance Biotherapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Iovance earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Iovance to the Biotechnology industry mean.
  • A Net Profit Margin of -24,145.0% means that €-241.45 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Iovance Biotherapeutics Inc:

  • The MRQ is -24,145.0%. The company is making a huge loss. -2
  • The TTM is -23,290.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-24,145.0%TTM-23,290.1%-854.9%
TTM-23,290.1%YOY--23,290.1%
TTM-23,290.1%5Y-5,175.6%-18,114.6%
5Y-5,175.6%10Y-5,175.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24,145.0%-159.2%-23,985.8%
TTM-23,290.1%-202.3%-23,087.8%
YOY--263.0%+263.0%
5Y-5,175.6%-452.4%-4,723.2%
10Y-5,175.6%-589.0%-4,586.6%
1.1.2. Return on Assets

Shows how efficient Iovance is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Iovance to the Biotechnology industry mean.
  • -14.9% Return on Assets means that Iovance generated €-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Iovance Biotherapeutics Inc:

  • The MRQ is -14.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.9%TTM-13.8%-1.1%
TTM-13.8%YOY-15.9%+2.0%
TTM-13.8%5Y-13.4%-0.5%
5Y-13.4%10Y-13.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.9%-12.5%-2.4%
TTM-13.8%-12.2%-1.6%
YOY-15.9%-11.2%-4.7%
5Y-13.4%-13.3%-0.1%
10Y-13.4%-14.6%+1.2%
1.1.3. Return on Equity

Shows how efficient Iovance is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Iovance to the Biotechnology industry mean.
  • -19.9% Return on Equity means Iovance generated €-0.20 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Iovance Biotherapeutics Inc:

  • The MRQ is -19.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.9%TTM-17.8%-2.1%
TTM-17.8%YOY-21.0%+3.2%
TTM-17.8%5Y-16.5%-1.3%
5Y-16.5%10Y-16.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.9%-16.0%-3.9%
TTM-17.8%-15.8%-2.0%
YOY-21.0%-13.9%-7.1%
5Y-16.5%-18.2%+1.7%
10Y-16.5%-19.1%+2.6%

1.2. Operating Efficiency of Iovance Biotherapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Iovance is operating .

  • Measures how much profit Iovance makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Iovance to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Iovance Biotherapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-11,563.7%+11,563.7%
TTM-11,563.7%YOY--11,563.7%
TTM-11,563.7%5Y-2,569.7%-8,994.0%
5Y-2,569.7%10Y-2,569.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-11,563.7%-208.5%-11,355.2%
YOY--280.2%+280.2%
5Y-2,569.7%-459.9%-2,109.8%
10Y-2,569.7%-596.9%-1,972.8%
1.2.2. Operating Ratio

Measures how efficient Iovance is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 261.62 means that the operating costs are €261.62 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Iovance Biotherapeutics Inc:

  • The MRQ is 261.624. The company is inefficient in keeping operating costs low. -1
  • The TTM is 249.102. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ261.624TTM249.102+12.523
TTM249.102YOY-+249.102
TTM249.1025Y55.356+193.746
5Y55.35610Y55.3560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ261.6242.817+258.807
TTM249.1023.181+245.921
YOY-3.609-3.609
5Y55.3565.554+49.802
10Y55.3567.396+47.960

1.3. Liquidity of Iovance Biotherapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Iovance is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.79 means the company has €2.79 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Iovance Biotherapeutics Inc:

  • The MRQ is 2.791. The company is able to pay all its short-term debts. +1
  • The TTM is 4.351. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.791TTM4.351-1.561
TTM4.351YOY5.746-1.395
TTM4.3515Y7.743-3.391
5Y7.74310Y7.7430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7913.987-1.196
TTM4.3514.440-0.089
YOY5.7465.569+0.177
5Y7.7436.158+1.585
10Y7.7436.492+1.251
1.3.2. Quick Ratio

Measures if Iovance is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Iovance to the Biotechnology industry mean.
  • A Quick Ratio of 1.50 means the company can pay off €1.50 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Iovance Biotherapeutics Inc:

  • The MRQ is 1.497. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 0.928. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ1.497TTM0.928+0.569
TTM0.928YOY3.916-2.988
TTM0.9285Y5.730-4.802
5Y5.73010Y5.7300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4973.653-2.156
TTM0.9284.158-3.230
YOY3.9165.515-1.599
5Y5.7306.012-0.282
10Y5.7306.206-0.476

1.4. Solvency of Iovance Biotherapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Iovance assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Iovance to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.25 means that Iovance assets are financed with 25.1% credit (debt) and the remaining percentage (100% - 25.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Iovance Biotherapeutics Inc:

  • The MRQ is 0.251. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.222. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.251TTM0.222+0.029
TTM0.222YOY0.241-0.019
TTM0.2225Y0.176+0.045
5Y0.17610Y0.1760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2510.336-0.085
TTM0.2220.330-0.108
YOY0.2410.267-0.026
5Y0.1760.367-0.191
10Y0.1760.378-0.202
1.4.2. Debt to Equity Ratio

Measures if Iovance is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Iovance to the Biotechnology industry mean.
  • A Debt to Equity ratio of 33.5% means that company has €0.33 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Iovance Biotherapeutics Inc:

  • The MRQ is 0.335. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.286. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.335TTM0.286+0.049
TTM0.286YOY0.320-0.033
TTM0.2865Y0.220+0.066
5Y0.22010Y0.2200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3350.376-0.041
TTM0.2860.398-0.112
YOY0.3200.334-0.014
5Y0.2200.431-0.211
10Y0.2200.476-0.256

2. Market Valuation of Iovance Biotherapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Iovance generates.

  • Above 15 is considered overpriced but always compare Iovance to the Biotechnology industry mean.
  • A PE ratio of -5.09 means the investor is paying €-5.09 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Iovance Biotherapeutics Inc:

  • The EOD is -8.377. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.088. Based on the earnings, the company is expensive. -2
  • The TTM is -4.117. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.377MRQ-5.088-3.289
MRQ-5.088TTM-4.117-0.971
TTM-4.117YOY-7.891+3.774
TTM-4.1175Y-17.569+13.452
5Y-17.56910Y-17.5690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.377-2.697-5.680
MRQ-5.088-2.422-2.666
TTM-4.117-2.709-1.408
YOY-7.891-4.116-3.775
5Y-17.569-6.257-11.312
10Y-17.569-6.478-11.091
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Iovance Biotherapeutics Inc:

  • The EOD is -11.142. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.767. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.792. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.142MRQ-6.767-4.375
MRQ-6.767TTM-4.792-1.975
TTM-4.792YOY-9.817+5.025
TTM-4.7925Y-16.640+11.848
5Y-16.64010Y-16.6400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.142-3.344-7.798
MRQ-6.767-2.939-3.828
TTM-4.792-3.486-1.306
YOY-9.817-5.592-4.225
5Y-16.640-8.464-8.176
10Y-16.640-8.872-7.768
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Iovance is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.05 means the investor is paying €4.05 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Iovance Biotherapeutics Inc:

  • The EOD is 6.670. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.051. Based on the equity, the company is fair priced.
  • The TTM is 2.968. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD6.670MRQ4.051+2.619
MRQ4.051TTM2.968+1.084
TTM2.968YOY6.407-3.439
TTM2.9685Y10.410-7.443
5Y10.41010Y10.4100.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.6702.198+4.472
MRQ4.0512.042+2.009
TTM2.9682.121+0.847
YOY6.4072.907+3.500
5Y10.4103.682+6.728
10Y10.4104.114+6.296
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Iovance Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2960.070-521%-0.101-66%0.108-375%0.108-375%
Book Value Per Share--1.9382.075-7%1.589+22%1.870+4%1.870+4%
Current Ratio--2.7914.351-36%5.746-51%7.743-64%7.743-64%
Debt To Asset Ratio--0.2510.222+13%0.241+4%0.176+42%0.176+42%
Debt To Equity Ratio--0.3350.286+17%0.320+5%0.220+52%0.220+52%
Dividend Per Share----0%-0%-0%-0%
Eps---0.386-0.367-5%-0.328-15%-0.286-26%-0.286-26%
Free Cash Flow Per Share---0.290-0.318+10%-0.260-11%-0.252-13%-0.252-13%
Free Cash Flow To Equity Per Share---0.287-0.148-48%-0.102-64%-0.001-100%-0.001-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---9.449--------
Intrinsic Value_10Y_min---8.230--------
Intrinsic Value_1Y_max---1.048--------
Intrinsic Value_1Y_min---1.030--------
Intrinsic Value_3Y_max---3.072--------
Intrinsic Value_3Y_min---2.935--------
Intrinsic Value_5Y_max---5.003--------
Intrinsic Value_5Y_min---4.651--------
Market Cap3605196100.000+39%2189616200.0001687259668.000+30%2836529241.000-23%4789928777.556-54%4789928777.556-54%
Net Profit Margin---241.450-232.901-4%--100%-51.756-79%-51.756-79%
Operating Margin----115.6370%-0%-25.6970%-25.6970%
Operating Ratio--261.624249.102+5%-+100%55.356+373%55.356+373%
Pb Ratio6.670+39%4.0512.968+37%6.407-37%10.410-61%10.410-61%
Pe Ratio-8.377-65%-5.088-4.117-19%-7.891+55%-17.569+245%-17.569+245%
Price Per Share12.925+39%7.8506.049+30%10.169-23%17.172-54%17.172-54%
Price To Free Cash Flow Ratio-11.142-65%-6.767-4.792-29%-9.817+45%-16.640+146%-16.640+146%
Price To Total Gains Ratio-43.622-65%-26.494-6.206-77%-30.879+17%-97.973+270%-97.973+270%
Quick Ratio--1.4970.928+61%3.916-62%5.730-74%5.730-74%
Return On Assets---0.149-0.138-7%-0.159+6%-0.134-10%-0.134-10%
Return On Equity---0.199-0.178-10%-0.210+5%-0.165-17%-0.165-17%
Total Gains Per Share---0.2960.070-521%-0.101-66%0.108-375%0.108-375%
Usd Book Value--584631503.001626037563.462-7%479529176.618+22%564348694.404+4%564348694.404+4%
Usd Book Value Change Per Share---0.3210.076-521%-0.109-66%0.116-375%0.116-375%
Usd Book Value Per Share--2.0962.244-7%1.719+22%2.023+4%2.023+4%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.417-0.397-5%-0.355-15%-0.310-26%-0.310-26%
Usd Free Cash Flow---87501769.343-96030539.270+10%-78297978.053-11%-67487247.015-23%-67487247.015-23%
Usd Free Cash Flow Per Share---0.314-0.344+10%-0.281-11%-0.272-13%-0.272-13%
Usd Free Cash Flow To Equity Per Share---0.310-0.160-48%-0.110-64%-0.001-100%-0.001-100%
Usd Market Cap3899740621.370+39%2368507843.5401825108782.876+30%3068273679.990-23%5181265958.682-54%5181265958.682-54%
Usd Price Per Share13.981+39%8.4916.543+30%11.000-23%18.575-54%18.575-54%
Usd Profit---116382683.395-111012763.443-5%-98976382.503-15%-86381511.666-26%-86381511.666-26%
Usd Revenue--482015.255297259.408+62%-+100%66057.646+630%66057.646+630%
Usd Total Gains Per Share---0.3210.076-521%-0.109-66%0.116-375%0.116-375%
 EOD+5 -3MRQTTM+10 -22YOY+9 -235Y+7 -2510Y+7 -25

3.2. Fundamental Score

Let's check the fundamental score of Iovance Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.377
Price to Book Ratio (EOD)Between0-16.670
Net Profit Margin (MRQ)Greater than0-241.450
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.497
Current Ratio (MRQ)Greater than12.791
Debt to Asset Ratio (MRQ)Less than10.251
Debt to Equity Ratio (MRQ)Less than10.335
Return on Equity (MRQ)Greater than0.15-0.199
Return on Assets (MRQ)Greater than0.05-0.149
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Iovance Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.900
Ma 20Greater thanMa 5013.926
Ma 50Greater thanMa 10011.442
Ma 100Greater thanMa 2008.804
OpenGreater thanClose12.925
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets780,351
Total Liabilities195,738
Total Stockholder Equity584,613
 As reported
Total Liabilities 195,738
Total Stockholder Equity+ 584,613
Total Assets = 780,351

Assets

Total Assets780,351
Total Current Assets307,848
Long-term Assets472,503
Total Current Assets
Cash And Cash Equivalents 114,888
Short-term Investments 164,979
Net Receivables 151
Inventory 10,372
Other Current Assets 17,458
Total Current Assets  (as reported)307,848
Total Current Assets  (calculated)307,848
+/-0
Long-term Assets
Property Plant Equipment 176,545
Long-term Assets Other 66,700
Long-term Assets  (as reported)472,503
Long-term Assets  (calculated)243,245
+/- 229,258

Liabilities & Shareholders' Equity

Total Current Liabilities110,306
Long-term Liabilities85,432
Total Stockholder Equity584,613
Total Current Liabilities
Accounts payable 33,123
Total Current Liabilities  (as reported)110,306
Total Current Liabilities  (calculated)33,123
+/- 77,183
Long-term Liabilities
Long term Debt 1,000
Capital Lease Obligations Min Short Term Debt74,862
Long-term Liabilities  (as reported)85,432
Long-term Liabilities  (calculated)75,862
+/- 9,570
Total Stockholder Equity
Total Stockholder Equity (as reported)584,613
Total Stockholder Equity (calculated)0
+/- 584,613
Other
Capital Stock14
Common Stock Shares Outstanding 255,834
Net Invested Capital 585,610
Net Working Capital 197,542
Property Plant and Equipment Gross 204,458



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
395,746
344,655
288,298
817,567
782,294
768,458
750,573
852,790
828,825
777,333
701,251
610,878
545,924
663,982
824,767
757,293
852,315
780,351
780,351852,315757,293824,767663,982545,924610,878701,251777,333828,825852,790750,573768,458782,294817,567288,298344,655395,746
   > Total Current Assets 
367,307
316,493
256,381
782,654
723,590
636,100
605,218
666,640
583,026
507,956
489,968
431,593
369,884
479,116
637,781
274,878
382,586
307,848
307,848382,586274,878637,781479,116369,884431,593489,968507,956583,026666,640605,218636,100723,590782,654256,381316,493367,307
       Cash And Cash Equivalents 
38,889
13,969
52,540
160,614
68,310
67,329
131,954
82,763
58,590
78,229
92,360
108,075
118,366
231,731
543,484
230,010
267,720
114,888
114,888267,720230,010543,484231,731118,366108,07592,36078,22958,59082,763131,95467,32968,310160,61452,54013,96938,889
       Short-term Investments 
322,985
293,112
193,112
611,265
645,838
562,108
461,976
573,605
517,859
426,181
389,829
316,383
241,807
240,114
82,808
20,884
93,654
164,979
164,97993,65420,88482,808240,114241,807316,383389,829426,181517,859573,605461,976562,108645,838611,265193,112293,112322,985
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33
0
151
151033000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
7,271
11,489
14,231
12,017
17,458
17,45812,01714,23111,4897,2710000000000000
   > Long-term Assets 
28,439
28,162
31,917
34,913
58,704
132,358
145,355
186,150
245,799
269,377
211,283
179,285
176,040
6,430
186,986
482,415
469,729
472,503
472,503469,729482,415186,9866,430176,040179,285211,283269,377245,799186,150145,355132,35858,70434,91331,91728,16228,439
       Property Plant Equipment 
19,594
19,231
22,912
26,206
49,794
113,915
127,881
132,628
160,457
169,921
176,232
171,999
169,014
178,247
180,354
180,180
179,407
176,545
176,545179,407180,180180,354178,247169,014171,999176,232169,921160,457132,628127,881113,91549,79426,20622,91219,23119,594
       Long Term Investments 
0
0
0
0
0
0
10,227
46,288
78,247
91,588
27,701
0
0
0
0
0
0
0
000000027,70191,58878,24746,28810,227000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
235,511
223,610
0
0223,610235,511000000000000000
       Other Assets 
8,845
8,931
9,005
8,707
8,910
18,443
7,247
7,234
7,095
7,868
7,350
7,286
7,026
6,619
0
66,724
0
0
0066,72406,6197,0267,2867,3507,8687,0957,2347,24718,4438,9108,7079,0058,9318,845
> Total Liabilities 
40,683
45,684
44,985
59,258
70,453
111,960
103,142
108,377
130,495
155,674
149,259
138,188
152,188
164,344
157,886
178,724
178,307
195,738
195,738178,307178,724157,886164,344152,188138,188149,259155,674130,495108,377103,142111,96070,45359,25844,98545,68440,683
   > Total Current Liabilities 
34,613
39,084
39,545
54,905
64,390
54,871
55,059
60,534
64,766
89,200
77,075
64,192
79,245
91,485
87,274
88,643
90,955
110,306
110,30690,95588,64387,27491,48579,24564,19277,07589,20064,76660,53455,05954,87164,39054,90539,54539,08434,613
       Accounts payable 
9,921
15,567
10,614
10,238
24,794
13,513
13,369
21,914
12,181
27,377
20,454
20,009
24,255
26,603
31,572
31,157
19,274
33,123
33,12319,27431,15731,57226,60324,25520,00920,45427,37712,18121,91413,36913,51324,79410,23810,61415,5679,921
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
4,857
2,077
1,223
1,597
6,510
0
4,786
0
0
004,78606,5101,5971,2232,0774,857000000000
   > Long-term Liabilities 
6,070
6,600
5,440
4,353
6,063
57,089
48,083
47,843
65,729
66,474
72,184
73,996
72,943
72,859
70,612
90,081
87,352
85,432
85,43287,35290,08170,61272,85972,94373,99672,18466,47465,72947,84348,08357,0896,0634,3535,4406,6006,070
       Other Liabilities 
53
2,352
2,352
2,352
2,352
11,714
0
0
0
0
0
0
0
0
0
20,237
0
0
0020,23700000000011,7142,3522,3522,3522,35253
> Total Stockholder Equity
355,063
298,971
243,313
758,309
711,841
656,498
647,431
744,413
698,330
621,659
551,992
472,690
393,736
499,638
666,881
578,569
674,008
584,613
584,613674,008578,569666,881499,638393,736472,690551,992621,659698,330744,413647,431656,498711,841758,309243,313298,971355,063
   Common Stock
5
5
5
6
6
6
6
7
7
7
7
7
7
8
0
9
0
0
009087777776666555
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
239
220
912
317
155
19
96
33
-5
-601
-2,343
-2,697
-2,038
-902
0
325
0
0
003250-902-2,038-2,697-2,343-601-5339619155317912220239



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,189
Cost of Revenue-10,755
Gross Profit-9,566-9,566
 
Operating Income (+$)
Gross Profit-9,566
Operating Expense-461,748
Operating Income-460,559-471,314
 
Operating Expense (+$)
Research Development344,077
Selling General Administrative106,916
Selling And Marketing Expenses-
Operating Expense461,748450,993
 
Net Interest Income (+$)
Interest Income13,043
Interest Expense--
Other Finance Cost-0
Net Interest Income13,043
 
Pretax Income (+$)
Operating Income-460,559
Net Interest Income13,043
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-447,516-460,559
EBIT - interestExpense = 0
-444,037
-444,037
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--447,516
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-447,516
Tax Provision--3,479
Net Income From Continuing Ops-444,037-444,037
Net Income-444,037
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--13,043
 

Technical Analysis of Iovance
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Iovance. The general trend of Iovance is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Iovance's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Iovance Biotherapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 16.78 < 16.85.

The bearish price targets are: 12.68 > 11.74 > 10.50.

Tweet this
Iovance Biotherapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Iovance Biotherapeutics Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Iovance Biotherapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Iovance Biotherapeutics Inc. The current macd is 0.2547091.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Iovance price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Iovance. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Iovance price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Iovance Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartIovance Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Iovance Biotherapeutics Inc. The current adx is 25.44.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Iovance shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Iovance Biotherapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Iovance Biotherapeutics Inc. The current sar is 13.82.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Iovance Biotherapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Iovance Biotherapeutics Inc. The current rsi is 48.90. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Iovance Biotherapeutics Inc Daily Relative Strength Index (RSI) ChartIovance Biotherapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Iovance Biotherapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Iovance price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Iovance Biotherapeutics Inc Daily Stochastic Oscillator ChartIovance Biotherapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Iovance Biotherapeutics Inc. The current cci is -72.6446873.

Iovance Biotherapeutics Inc Daily Commodity Channel Index (CCI) ChartIovance Biotherapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Iovance Biotherapeutics Inc. The current cmo is -12.76625014.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Iovance Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartIovance Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Iovance Biotherapeutics Inc. The current willr is -84.34504792.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Iovance Biotherapeutics Inc Daily Williams %R ChartIovance Biotherapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Iovance Biotherapeutics Inc. The current atr is 0.63518507.

Iovance Biotherapeutics Inc Daily Average True Range (ATR) ChartIovance Biotherapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Iovance Biotherapeutics Inc. The current obv is -8,365.

Iovance Biotherapeutics Inc Daily On-Balance Volume (OBV) ChartIovance Biotherapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Iovance Biotherapeutics Inc. The current mfi is 31.08.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Iovance Biotherapeutics Inc Daily Money Flow Index (MFI) ChartIovance Biotherapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Iovance Biotherapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-09 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-10 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-14 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-22 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-24 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-17 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-12 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-19 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-12 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Iovance Biotherapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Iovance Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.900
Ma 20Greater thanMa 5013.926
Ma 50Greater thanMa 10011.442
Ma 100Greater thanMa 2008.804
OpenGreater thanClose12.925
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Iovance with someone you think should read this too:
  • Are you bullish or bearish on Iovance? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Iovance? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Iovance Biotherapeutics Inc

I send you an email if I find something interesting about Iovance Biotherapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Iovance Biotherapeutics Inc.

Receive notifications about Iovance Biotherapeutics Inc in your mailbox!